Enzyme therapy in patients with advanced colorectal cancer
Klek S., Popiela T., Kulig J., Wachol D., Bock P.R., Hanish J., Stauder G.
4th
Annual Meeting of European Society of Surgery, Krakow, Dec.3-6, 2000
published in Przeglad lekarski 2000, 57, Suppl.6, abst. 74, pp. 4 - ISSN
00332240
74 KA (19-13-3)
Introduction:
The cancer of the colon is one of the most frequent malignant diseases in
Europe. Its therapy (both curative or paliative) includes resection, radio- and
chemotherapy. One of the new methods is enzyme therapy. Reports on positive
effects of hydrolytic agents in oncologic diseases have been known for more than
20 years. Enzymes can start cell mediated attack on tumor cells by increasing
the improvement of monocytic phagocytosis and activation of killer cells.
Aim:
a multicentre retrolective cohort analysis with two parallel groups (one
group standard therapy, the other standard therapy + Wobe Mugos) was performed
to analyze effects of an additional treatment with enzymes.
Methods:
1242 patients in 213 centers were included and evaluated (616 patients with
enzymes and 626 patients with standard therapy only). 92,5% of patients in
enzyme group and 94,6% in control group were treated surgically. Patients of
both groups received a tumor-destructive therapy (chemo- and radiotherapy) and
additionally various forms of aftercare (echinacea, thymus, selen, etc.). Groups
were comparable.
Results:
In patients with disease stage Dukes D patients' number and observation time
was sufficient to analyze survival; in this group a distinct effect of enzymes
on median survival was found. Treatment with enzymes significantly reduced
number and severity of adverse reactions of the basic chemo- and radiotherapy
(34,2% of test group vs. 63,7% of control group)